sensitive to stabilization by iminosugars, which bind at the active site to provide the proper conformation. Thus the stabilized protein may escape from degradation processes, and reach the lysosomes in an active state, as proposed for enzyme enhancement therapy (EET). In this work the influence <strong>of</strong> novel derivatives <strong>of</strong> 1-deoxygalactonojirimycin (DGJ) on the β-Gal activity <strong>of</strong> cultured GM1 and MBD skin fibroblasts was examined. Furthermore, the effect <strong>of</strong> selected compounds on natural substrate degradation in GM1 and MBD cells was determined. Several novel iminosugars acting as pharmacological chaperones <strong>of</strong> β-Gal in specific GM1 fibroblasts were discovered and described in this work. One specific compound, DLHex-DGJ, proved to be a potent competitive inhibitor <strong>of</strong> β-Gal in vitro, and this work describes its effects on activity, protein expression, maturation and intracellular transport in vivo in 13 fibroblast lines with GLB1 mutations. DLHex-DGJ significantly increased the catalytic activity in six GM1 cell lines, and normalization <strong>of</strong> transport and lysosomal processing <strong>of</strong> β-Gal precursors was demonstrated for selected cell lines. Furthermore, DLHex-DGJ and another, similar compound successfully reduced the level <strong>of</strong> internalized radiolabeled G M1 -gangliosides in a specific GM1 cell line, suggesting that reduction <strong>of</strong> stored material is possible under certain conditions. Specific antibodies, directed against human β-Gal, were developed with the aid <strong>of</strong> previously published protocols, and novel approaches to obtain large amounts <strong>of</strong> the purified human enzyme were tested. Two novel polyclonal anti-β-Gal peptide antibodies were produced and expression <strong>of</strong> human β-Gal in E. coli cells may provide the basis for further development <strong>of</strong> antibodies directed against the human enzyme. Large parts <strong>of</strong> this thesis were carried out at the <strong>University</strong> hospital under the guidance and supervision <strong>of</strong> Pr<strong>of</strong>. Pascke. International cooperations Maria Abramic, Ruder Boskovic <strong>Institute</strong> Zagreb, Croatia Steve Ealick, Cornell <strong>University</strong>, Ithaca, U.S.A. Toni Kutchan, Donald Danforth Plant Science Center, St. Louis, U.S.A. Shwu Liaw, National Yang-Ming <strong>University</strong>, Taipei, Taiwan Matthias Mack, Hochschule Mannheim, Germany Bruce Palfey, <strong>University</strong> <strong>of</strong> Michigan, Ann Arbor, U.S.A. Research projects FWF P22361: “Mechanism <strong>of</strong> redox controlled protein degradation” FWF P19858: “Enzymes <strong>of</strong> nikkomycin biosynthesis” FWF-Doktoratskolleg “Molecular Enzymology” WTZ <strong>Austria</strong>-Croatia “Structure-function relationships in metallopeptidases <strong>of</strong> the M49 family” Publications 1) Durchschein, K., Ferreira-da Silva, B., Wallner, S., Macheroux, P., Kroutil, W., Glueck, S. M., Faber, K.: The flavoprotein-catalyzed reduction <strong>of</strong> aliphatic nitro-compounds represents a biocatalytic equivalent to the Nef-reaction, Green Chemistry, 2010, 12:616- 619. 14
2) Jajcanin-Jozic, N., Deller, S., Pavkov, T., Macheroux, P., Abramic, M.: Identification <strong>of</strong> the reactive cysteine residues in yeast dipeptidyl peptidase III, Biochimie, 2010, 92:89- 96. Award Dissertation Award <strong>of</strong> the <strong>Austria</strong>n Society for Molecular Biosciences and Biotechnology (ÖGMBT) to Andreas Winkler for his dissertation on “Structure-function studies on berberine bridge enzyme (BBE) from the California poppy, Eschscholzia californica”. Dr. Andreas Winkler was a PhD student in the Doktoratskolleg “Molecular Enzymology” and is now a postdoctoral fellow at the Max-Planck <strong>Institute</strong> for Molecular Medicine in Heidelberg, Germany. 15